IL90529A - Compositions for inhibiting the influx of leukocytes into organs during sepsis or other trauma - Google Patents

Compositions for inhibiting the influx of leukocytes into organs during sepsis or other trauma

Info

Publication number
IL90529A
IL90529A IL9052989A IL9052989A IL90529A IL 90529 A IL90529 A IL 90529A IL 9052989 A IL9052989 A IL 9052989A IL 9052989 A IL9052989 A IL 9052989A IL 90529 A IL90529 A IL 90529A
Authority
IL
Israel
Prior art keywords
composition
antibody
administration
leukocytes
inflammation
Prior art date
Application number
IL9052989A
Other languages
English (en)
Other versions
IL90529A0 (en
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of IL90529A0 publication Critical patent/IL90529A0/xx
Publication of IL90529A publication Critical patent/IL90529A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL9052989A 1988-06-07 1989-06-05 Compositions for inhibiting the influx of leukocytes into organs during sepsis or other trauma IL90529A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20403788A 1988-06-07 1988-06-07
US07/331,450 US5147637A (en) 1988-06-07 1989-03-31 Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma

Publications (2)

Publication Number Publication Date
IL90529A0 IL90529A0 (en) 1990-01-18
IL90529A true IL90529A (en) 1994-01-25

Family

ID=26899117

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9052989A IL90529A (en) 1988-06-07 1989-06-05 Compositions for inhibiting the influx of leukocytes into organs during sepsis or other trauma

Country Status (10)

Country Link
US (1) US5147637A (de)
EP (1) EP0346078A3 (de)
JP (1) JPH02104534A (de)
KR (1) KR910000184A (de)
AU (1) AU620100B2 (de)
DK (1) DK278589A (de)
FI (1) FI892793A7 (de)
IL (1) IL90529A (de)
NO (1) NO892319L (de)
PT (1) PT90775B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2095876T3 (es) * 1989-06-02 1997-03-01 Univ Johns Hopkins Med Anticuerpos monoclonales contra la cadena beta de receptores de adhesion de leucocitos; procedimiento de produccion de estos anticuerpos y utilizacion
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
DE4019024A1 (de) * 1990-06-14 1991-12-19 Bayer Ag Verwendung der efomycine a, e und g als entzuendungshemmende mittel
WO1992003473A1 (en) * 1990-08-27 1992-03-05 Cetus Corporation Cd18 peptide medicaments for the treatment of disease
ATE166230T1 (de) * 1990-08-31 1998-06-15 Boehringer Ingelheim Pharma Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
EP0565642A1 (de) * 1991-01-11 1993-10-20 Repligen Corporation Methode zur verhinderung entzündlicher schäden
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
EP0507187B1 (de) * 1991-04-03 1996-12-04 Boehringer Ingelheim Pharmaceuticals Inc. Verfahren zur Hemmung der Sauerstofftoxizität in den Lungen
US5932217A (en) * 1991-05-03 1999-08-03 The Rockefeller University Peptides which inhibit adhesion between leukocytes and endothelial cells
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
DE69229275T2 (de) * 1991-10-04 1999-12-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
GB9126918D0 (en) * 1991-12-19 1992-02-19 Univ London Members of specific binding pairs;methods of their making and using
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
JPH07506566A (ja) * 1992-02-12 1995-07-20 バイオゲン　インコーポレイテッド 炎症性胃腸病の処置
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
EP1069182A1 (de) * 1992-07-16 2001-01-17 Icos Corporation Erleichterung von Symptomen die mit entzündlichen Krankheitszuständen verbunden sind, unter Verwendung von Antikörpern gegen CD18
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
WO1994012214A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US20020081294A1 (en) * 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002540078A (ja) 1999-03-19 2002-11-26 ジェネンテック・インコーポレーテッド Ｌｆａ−１アンタゴニスト投与量の増加によるｌｆａ−１関連疾患の治療
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
AU6068100A (en) * 1999-07-06 2001-01-22 Johns Hopkins University, The Method and composition for inhibition of vasospasm
JP2003527439A (ja) 2000-03-17 2003-09-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 抗ｃｄ１８抗体と抗ｃｃｒ２抗体の混合物を用いる狭窄および再狭窄を抑制する方法
WO2001070260A1 (en) * 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Cd18-binding antibodies inhibit stenosis-related disorders
RU2006146939A (ru) 2004-06-09 2008-07-20 Дженентек Способ лечения кольцевидной гранулемы или саркоида
CA2589746A1 (en) * 2004-12-08 2006-06-15 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20110177969A1 (en) * 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
CA2901413A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of vasculitis
ES2654093T3 (es) 2013-03-13 2018-02-12 Inflammatory Response Research, Inc. Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes
RU2672871C2 (ru) 2013-03-13 2018-11-20 Инфламматори Респонс Ресёрч, Инк. Применение левоцетиризина и монтелукаста при лечении травматических повреждений
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
EP4153178A4 (de) 2020-05-19 2024-06-05 Irr, Inc. Levocetirizin und montelukast bei der behandlung von sepsis und symptomen davon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
EP0303692A4 (en) * 1987-02-26 1990-12-05 Dana Farber Cancer Institute Cloning of lfa-1
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US4935237A (en) * 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
US4797277A (en) * 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy

Also Published As

Publication number Publication date
AU620100B2 (en) 1992-02-13
NO892319L (no) 1989-12-08
AU3608489A (en) 1989-12-14
KR910000184A (ko) 1991-01-29
FI892793L (fi) 1989-12-08
IL90529A0 (en) 1990-01-18
EP0346078A3 (de) 1991-03-20
FI892793A7 (fi) 1989-12-08
DK278589D0 (da) 1989-06-07
PT90775B (pt) 1994-11-30
NO892319D0 (no) 1989-06-06
EP0346078A2 (de) 1989-12-13
JPH02104534A (ja) 1990-04-17
DK278589A (da) 1989-12-08
PT90775A (pt) 1989-12-29
US5147637A (en) 1992-09-15
FI892793A0 (fi) 1989-06-07

Similar Documents

Publication Publication Date Title
US5147637A (en) Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
Odenholt Pharmacodynamic effects of subinhibitory antibiotic concentrations
Dominioni et al. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater
Wade et al. Piperacillin or ticarcillin plus amikacin: a double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients
JPH07501545A (ja) 非連鎖球菌系細菌感染症の治療方法
Rolston et al. Pseudomonas aeruginosa infection in cancer patients: Infectious complications of cancer
US5322699A (en) Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
JP2005511645A (ja) 微生物感染の治療
Gnann Jr et al. Ceftriaxone: in vitro studies and clinical evaluation
Bayer et al. Valve site-specific pathogenetic differences between right-sided and left-sided bacterial endocarditis
Morse et al. Once weekly intraperitoneal therapy for gram-positive peritonitis
Täuber et al. General principles of therapy of pyogenic meningitis
Young Fever and septicemia
WO2003041726A1 (en) Use of an extracellular adherence protein for the manufacture of an anti-inflammatory drug
EP0486609B1 (de) Pharmazeutisches produkt für die behandlung von sepsis
Dalle et al. Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer
NZ229434A (en) Anti-cd18 antibodies, their use and compositions thereof for inhibiting leukocyte influx
US6315999B1 (en) Pharmaceutical product for the treatment of sepsis
Jenkinson et al. Cefotaxime in the treatment of pneumococcal pneumonia
TUOMANEN et al. New antibodies as adjunctive therapies for gram-positive bacterial meningitis
Novakova et al. Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients
Stephens ICU complications of hematopoietic stem cell transplant, including graft vs host disease
EP0584273B1 (de) Endothelzell-Ligand für den Leukocyten CR3 erkennender Antikörper
Woodnutt et al. Temocillin efficacy in experimental Klebsiella pneumoniae meningitis after infusion into rabbit plasma to simulate antibiotic concentrations in human serum
AU6122894A (en) Method for modulating transendothelial migration of cells promoting inflammation, and related methods of measurement thereof

Legal Events

Date Code Title Description
RH Patent void